Overview
DCTH market data
Price History
DCTH price chart
Valuation & Profitability
- P/E (TTM)
- 1,117.60 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.07 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.65 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 0.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.12 – $17.42 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $594.6M · P/B 3.21 · P/S 6.23.
Company News
8-K filing — DELCATH SYSTEMS, INC. (DCTH)SEC EDGAR · Aug 14, 2026, 12:09 PM
HC Wainwright & Co. Maintains Buy on Delcath Systems, Raises Price Target to $32Benzinga · Aug 7, 2026, 11:10 AM
BTIG Maintains Buy on Delcath Systems, Raises Price Target to $21Benzinga · Aug 6, 2026, 6:40 PM
Delcath Systems shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY26 sales guidance above estimates.Benzinga · Aug 6, 2026, 12:47 PM
Delcath Systems Q2 EPS $0.07 Beats $(0.09) Estimate, Sales $29.133M Beat $26.259M EstimateBenzinga · Aug 6, 2026, 12:04 PM
Delcath Systems Sees FY2026 Sales $104.000M-$108.000M vs $103.242M EstBenzinga · Aug 6, 2026, 12:01 PM
Delcath Systems Doses First Patient In Phase 2 Clinical Trial Of HEPZATOBenzinga · Jul 9, 2026, 12:10 PM